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Mantle cell lymphoma (MCL) is a hematologicalmalignancywithunfavorable prognosis.Novel therapeutic approaches
for treating the disease are aimed at the mechanisms regulating growth signals, cellular proliferation, and survival
pathways of themalignant clones. Bortezomib (Brt), a proteasome inhibitor with pleiotropic activities was shown to be
active in MCL and is currently implemented in therapeutic combinations for this disease. Telomerase activity is
essential for survival of malignant cells and as such is considered a valid therapeutic target. This study evaluated the
effects of bortezomib on telomerase activity and its regulation in MCL cells in vitro and ex vivo.
Our study shows that bortezomib exerts a cytotoxic effect in a dose dependent manner in two MCL cell lines, with
differential sensitivity.While the IC50 for HBL-2 cells ranged between 2.5 ng/ml to 1.5 ng/ml during24-72 h respectively,
the IC50 for the NCEB cells was twice. Bortezomib differentially inhibited telomerase activity (TA): in HBL-2 cells there
was a decline of 20%-55% during 24-72 h respectively. However in NCEB cells the decline wasmuch smaller, and did
not exceed 25%. Inhibition of telomerase activity is shown to be operated by two separate mechanisms: reduction of
the hTERTmRNAexpression (controlled by the binding of transcription factors) and reduction in phosphorylation of the
catalytic subunit of hTERT by its kinases, AKT and PKCα.
A decrease in telomerase activity was demonstrated also in mononuclear cells, isolated from three MCL patients
following incubation of the cells in the presence of bortezomib for 24-72 h. In one patient the decrease in TA ranged
between 17%-37% respectively, in the second patient between 63%-76% and in the third patient between 70-100% for
24-72 h respectively.
The current study indicates that a combination of bortezomib and rapamycin, (an m-Tor pathway inhibitor used in MCL
treatment) inducedsynergistic inhibitionof telomerase activity. InHBL-2 cells, the combined treatment of bortezomib and
rapamycin decreasedTAby80%compared to the expected value (40%) and forNCEBcells a similar trendwasobserved.
In contrast, there was neither additive nor synergistic effect of this combination on cell proliferation.
In the light of the crucial role of telomerase in cancer cells, it was important to characterize the possible relations between
telomerase and bortezomib and to distinguish the biochemical mechanisms of its regulation and its interactions with
other signal transduction inhibitors such as rapamycin. The results of this work encourage the in vivo examination of the
therapeutic potential of the combination of bortezomib and rapamycin in Mantle Cell Lymphoma patients.
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MCL is a subtype of B-cell lymphoma accounting for 5–10% of all non-
Hodgkin’s lymphomas [12]. MCL patients have one of the worst prognoses
among lymphomas with a median survival of approximately 3 years [12].
Recent studies have identified new drugs active in MCL, among
them proteasome inhibitors and mammalian target of rapamycin
(mTOR) inhibitors [13]. The proteasome inhibitor bortezomib (Brt)
has been recently approved for treatment of this disease.
The ubiquitin-proteasome pathway plays a critical role in many
cellular functions such as cell cycle control and modulation of the
transcription factor NFκB [1]. Proteasome inhibitors lead to tumor
growth arrest, induce cell death, and inhibit tumor metastasis and
angiogenesis [6]. Although many mechanisms of Brt action on MCL
cells are known, the fact that it is a proteasome inhibitor suggests that
other cellular targets may be affected by its inhibition as well. This
inhibition is achieved by the binding of Brt to the catalytic site of the
26S proteasome with high affinity and specificity.
The mTOR kinase, another key player in the pathogenesis of
MCL, regulates mRNA translation which enhances the translation of
cyclin-D1. The activity of mTOR can be inhibited by rapamycin
analogs [13] and which are effective in MCL treatment.
The importance of telomerase in the biology and prognosis of many
types of cancers including MCL is well established [17]. Telomerase is a
unique reverse transcriptase expressed almost exclusively inN 90%of cancer
cells. It compensates for telomeric loss in eachDNA replication (Blackburn
and Collins, 2010) thus conferring endless replicative potential to the
cancer cell. Due to its essentiality and specificity to themalignant cell itmay
serve as a valid anticancer drug target and indeed active compounds that
target telomerase are already in advanced phases of clinical trials (Shay and
Wright, 2005). The importance of telomerase in MM has been
demonstrated convincingly both in vitro and clinically. Telomerase activity
has been found in MCL cells of 90% of the newly diagnosed and relapsed
patients, while only in 13% of patients in remission [17]. It has also a
prognostic value as elevated activity of the enzyme is correlated with poor
prognosis [18]. These may be related to the fact that a recurrent breakpoint
region in MCL involves the hTERT (human telomerase) locus
on chromosome 5p [15]. Numerous cytotoxic drugs target telomerase
(Mor-Tzuntz et al, 2010; Uziel et al, 2005; Dong et al, 2009). We also
showed that bortezomib down regulates telomerase activity in myeloma
cells and this inhibition may have clinical implications [16]. In the light of
common signaling pathways connecting telomerase regulation and
bortezomib mechanisms of action such as the NFκB axis we surmised
that the drug may affect the activity of telomerase in MCL cells. In the
current paper we present data regarding the effect of the drug on TA in
MCL cells and analyze the regulatory pathways leading to this inhibitory
effect.We also evaluated the possible synergistic effect of Brt and rapamycin
on telomerase activity. Additionally, we assessed the effect of Brt on TA in
other cancer and non-cancer cell lines. While most of the work was
performed in vitrowe were able to show also that the samemechanisms are
relevant in vivo, by analyzing cells isolated from bone marrow aspirates of
MCL patients before and after Brt treatment and ex vivo exposure to the
drug. In addition, we found that telomerase response to bortezomibmay be
correlated with clinical response in patients with MCL.Materials and methods
Cell culture
The experimental system was based on two MCL cell lines, Ewing
sarcoma cell line and non malignant keratinocyte line. MCL cell linesHBL-2 and NCEB were obtained from the Germany Type Culture
Collection and fromProf. Priel's laboratory at theBen-GurionUniversity,
Beer- Sheva, Israel. SK-N-MC cell line (Ewing sarcoma) was kindly
provided by Dr. Gad Lavie (Sheba Medical Center, Ramat-Gan, Israel).
Cells were cultured in RPMI-1640 with 10% FBS (HBL-2, SK-N-MC),
or 20% (NCEB), containing 2 mM L-Glutamine, 100 units/ml
penicillin, and 100 μg/ml streptomycin. All ingredients were purchased
from Biological Industries Beit Haemek, Israel. Keratinocytes (kindly
donated by Dr. Amiram Ravid, FMRC, Israel) were cultured in MEM-
EAGLE, supplemented with 10% fetal calf serum, containing 1% L-
Glutamine, 20μg/l D-calcium pantothenate, 100units/ml penicillin, and
100 μg/ml streptomycin. Cells from MCL patients (after obtaining
informed consent) were isolated from blood samples by the Ficoll-
Hypaque density gradient.
Cell viability and proliferation assays
Proliferation and viability were assessed by the WST-1 assay (Roche,
Basel Switzerland) and by Trypan Blue exclusion. WST-1 measures the
activity of mitochondrial dehydrogenases that cleave the WST-1 to a
formazan dye and is proportional to cell number. This is followed by
measuring the absorbance at 450 nm in a microplate reader. Cells were
cultured in 96-well plates for 24, 48, and 72 h with or without Brt. After
incubation, 10% of theWST-1 reagent was added and further incubated
at 37 °C for 2 h [2]. The effect of rapamycin on cell proliferation was
evaluated by the WST-1 method. Control cells were grown in the
presence of DMSO (used as a solvent for rapamycin) at 0 - 500 nM. SK-
N-MC and keratinocytes proliferation was determined by the
sulforhodamine B (SRB) assay as previously described [19]. Basically,
this assay measures the amounts of cellular proteins which correlate to the
number of viable cells.
Telomerase activity assay
Telomerase activity was assessed by the TRAP assay (TRAPeze kit,
Millipore) according to the manufacturer’s instructions in samples
which were exposed to the IC50 dose of bortezomib. Cells were lysed
with ice cold CHAPS lysis buffer, 50-100 ng of protein extracts were
subjected to PCR in the presence of TS primer. The PCR products were
separated on 12.5% PAGE and were stained with Nucleic Acid Gel
Stain (Lonza, Basel Switzerland). Quantification was performed by the
Quantity One software in the Versa-Doc device. TA was calculated
according to the following formula: TPG= [(X −B)/C]:[(r −B)/Cr 100],
where TPG is the total product generated, X signifies each sample signal,
B is the gel background, C represents the 36 bp internal PCR control, r is
the TSR8 quantification control.
Real-time PCR for hTERT expression
The expression of the hTERT gene was detected by Real Time PCR.
Total RNA was extracted from cells using EZ-RNA Isolation Kit reagent
(Biological Industries Beit Haemek, Israel). The extracted RNA was
reverse transcribed according to the manufacturer's instructions of the
High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems,
CA. USA). The real-time quantitative RT-PCR is based on the TaqMan
methodology, ABI PRISM 7000 Sequence Detection System (Applied
Biosystems, CA. USA). hTERT gene expression was calculated relatively
to the expression of the control gene HPRT-1.
Chromatin Immunoprecipitation (ChIP) assay
The involvement of NFκB, c-Myc and SP1 in the inhibitory effect
of bortezomib in MCL cells was assessed by the Chromatin
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EZ ChIP kit according to the manufacturer’s instructions (Upstate,
Temecula, CA) and as previously described [16]. The level of the
DNA binding of SP1, c-Myc and NFκB was evaluated relatively to
the total DNA input of each sample that was not immunoprecipitated
with any of the antibodies. The antibodies against SP1 and c-Myc
were purchased from Millipore MA, USA. The antibodies against
NFκB were purchased from Abcam MA, USA. The relevant primers
with the following sequences are as follows:
For the region of c-Myc and SP-1 binding site:
Forward primer: AGTGGATTCGCGGGCACAGA;
Reverse primer: TTCCCACGTGCGCAGCAGGA
For the region of NFκB binding site:
Forward primer: GCCTCCTAGCTCTGCAGT
Reverse primer: ACCCGAGGACGCATTGCT
Due to the high GC content in the hTERT promoter region, PCR
reactions included several additional temperature steps (in the
polymerization stage) to ensure proper products formation. PCR
conditions were as follows:
94°C – 3 min, followed by 36 cycles of: 94°C- 20 sec, 58°C- 30 sec,
72°C- 20 sec, 76°C- 20 sec, 80°C- 20 sec 84°C- 20 sec, and finally
72°C- 5 min. The products were separated on a 1% agarose gels and
analyzed by the VersaDoc software on the Gel Doc documentation
system (BioRad, Israel).
Immunoprecipitation and Western blot analysis
To determine the phosphorylated hTERT level, an immunopre-
cipitation assay was used. 500-1000 μg of protein was precipitated
with 10 μg/mg anti-phosphoserine antibody (StressMarq Biosciences
Inc.) or with 20 μg/mg anti-total hTERT antibody (Santa Cruz, CA,
USA). The protein-antibody complexes were mixed with 20 μg of
protein G agarose beads for 16 h agitation in 4°C. The
immunoprecipitated lysates were washed with 1XCHAPS lysis buffer
(obtained from the TRAPEZE kit) and boiled for 3 min. for standard
Western blot analysis, as described below. The primary anti-hTERT
antibody for the immunobloting (1:500-1:1000) was purchased from
Epitomics, CA, USA.
The phosphorylation states of telomerase and its kinases, phospho-
AKT (p-AKT) and phospho PKCα (p-PCKα), were evaluated by
Western blotting. Cells were grown in absence of serum for 24 h, Brt and
serum were added for 30 min and lysates were prepared by using the
CHAPS lysis buffer (from the TRAPEZE kit) containing phosphatase
and protease inhibitors. Identical protein amounts (100 μg) were
separated by 10% SDS-PAGE, transferred to nitrocellulose membrane
and then detected by the following antibodies: anti-pAKT Ser473/
pPKCα Ser657 and anti-total AKT/PKCα. (anti-AKT: 1:1000, Cell
signaling SC, USA; anti-PKCα: 1:500, Santa Cruz Biotechnology, CA,
USA). Signals were visualized after exposing the membranes to 2nd
fluorescent antibodies and quantified by the Odyssey analysis software.
The protein phosphatase level of total PP2A in cellular lysates was
determined after Brt treatment for 24 h by Western blot analysis.
Antibodies against the three subunits of PP2A: a, b and c were used (Cell
Signaling, Boston, MA, USA).
Statistical Analysis
A two-tailed One-sample Student t test with unequal variance and
ANOVA one way were used to calculate the P values in SPSS forWindows version 11.5 software (SPSS, Inc., Chicago, IL). In all
assays, P values b0.05 and 0.001 were considered statistically
significant and highly significant, respectively.
Results
The effect of Brt on proliferation of MCL cell lines
The proliferation of HBL-2 and NCEB cells was monitored after
the administration of bortezomib for 24, 48 and 72 h. Bortezomib
inhibited cell proliferation in a dose dependent manner in both cell
lines (Figure 1 A, B). NCEB cells were less sensitive to inhibition
with IC50 value of 5 ng/ml while the IC50 for HBL-2 cells was
2.5 ng/ml after 24 h. After exposure of 48 and 72 h the IC50 of
HBL-2 decreased to 2 ng/ml and 1.5 ng/ml respectively. The IC50 of
NCEB did not decrease over time and remained 5 ng/ml (Figure 1B).
TA following treatment of MCL cell lines by Brt
MCL cells were exposed for 24 h, 48 h and 72 h to the respective
IC50 concentrations of Brt. TA was assessed by the TRAP assay.
Bortezomib decreased TA in HBL-2 cells by 55%, 40% and 20% at
24, 48 and 72 h, respectively (Figure 1D, E). In NCEB cells however,
TA was not affected by bortezomib (Figure 1 F). In addition,
mononuclear cells were isolated from three MCL patients, exposed
ex vivo to 2 ng/ml of Brt for 24 h, 48 h and 1.5 ng/ml for 72 h
(Figure 1G). The effect of bortezomib varied widely and ranged from
0% to more than 80% decrease in TA (Table 1). To examine whether
the down regulation of TA was a nonspecific result of reduced
proliferation the cell lysates of treated and non- treated cells were
analyzed for DNA polymerization activity of DNA polymerase α
(done in the laboratory of Dr. Mary Bakhanashvily, Sheba Medical
Center, Israel). There was no decrease in DNA polymerization
capacity of the enzyme indicating a specific effect of the drug on TA
(not shown). To clarify whether telomerase inhibition was mediated
by a direct interaction of the drug with the enzyme, relevant doses of
Brt were added to cell lysates for 30 min prior to the TRAP assay. Brt
had no effect on TA in these settings (Figure 1C).
The effect of Brt on proliferation and TA of SK-N-MC
and keratinocytes
SK-N-MC cells were used to test the effect of Brt on non-MCL
cells. Cells were exposed to a wide range of Brt concentrations for 24
h and 48 h. Following 24 h treatment of the cells with Brt a decrease
of about 45% was observed at a dose of 20 ng/ml. Higher doses did
not changed this effect significantly (Figure 2A). Exposure of SK-N-
MC cells to Brt for 48 h resulted in a dose dependent decrease in cell
number. At 20 ng/ml all cells died (Figure 2B). The effect of Brt on
keratinocytes, non-cancer human epithelial cells [14] was determined
as well. Keratinocytes were also found to be sensitive to the cytotoxic
effect of Brt for 48 h with an IC50 of 4-8 ng/ml for 24 and 48 h,
respectively (Figure 2 C).
TA of SK-N-MC and keratinocytes following exposure to several
concentrations of Brt for 48 h was determined. The activity of
telomerase in SK-N-MC and in keratinocytes was reduced in a dose-
dependent manner (Figure 2A, B).
The effect of Brt on telomerase regulation
The regulation of telomerase is exerted on both transcriptional and
posttranslational levels.
Inhibition of hTERT expression by Brt. Cells were grown in the
presence of Brt (2.5 ng/ml for HBL-2 and 5 ng/ml for NCEB, for
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Figure 1. Proliferation and telomerase activity in response to Brt treatment. MCl cells were grown in the presence of a range of Brt
dosages and their proliferation was assessed by the WST-1 assay. A. HBL-2 c; B. NCEB cells. Cells were exposed to the IC50
concentration of Brt and their telomerase activity was measured by the TRAP assay. C. A representative example of the TRAP assay;
D. The activity of telomerase in HBL-2 cells; E. The activity of telomerase in NCEB cells. Mononuclear cells from bone marrow aspirates
were subjected to Brt at 2 or 1.5ng/ml for 24-72h and telomerase activity was measured thereafter. F. Representative TRAP assay.
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Treatment with Brt reduced the hTERT mRNA levels in HBL-2 cells.
However, the reduction in hTERT mRNA expression level of NCEB
cells was observed only at 16 h and not at 24 h. The estimation of the
hTERT gene expression was calculated relatively to the expression of
the control housekeeping gene, HPRT-1. The decrease of hTERTTable 1. Telomerase Activity inMononuclear Cells Isolated fromMCL Patients After Exposure to Brt
24h 48h 72h
Patient 1 37 17 20
Patient 2 76 67 63
Patient 3 100 81 70mRNA in HBL-2 after exposure to bortezomib for 16 h and 24 h was
45% and 25%, respectively (Figure 3A). Decreases of 30% and 5% in
hTERT mRNA was observed in NCEB cells after the administration of
Brt for 16 h and 24 h, respectively (Figure 3B).
Transcription factors binding to the hTERT promoter. The
involvement of NFkB, c-Myc and SP-1 in the transcriptional
regulation of hTERT was assessed by the ChIP assay, which measures
the level of the transcription factors binding to its promoter. The level
of the DNA binding of SP1, c-Myc and NFkB was evaluated
relatively to the total DNA input of each sample, which was not
immunoprecipitated with any of the antibodies. Brt reduced the
binding of all transcription factors to the promoter of hTERT in
HBL-2 cells (Figure 3 C, D). In NCEB cells, only the binding of SP1
was decreased after bortezomib treatment (Figure 3E).
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Figure 2. The activity of telomerase and cell proliferations in response to Brt treatments to non MCL cells. A. Proliferation of SK-N-MC
cells. Cells were exposed to Brt in escalating concentrations and their proliferation was measure by the SRB assay. B. Telomerase activity
of these cells after exposure of the IC50 dosage of Brt for 48h; C. Proliferation of keratinocytes. Cells were exposed to Brt in escalating
concentrations and their proliferation was measure by the SRB assay. D. Telomerase activity of these cells after exposure of the IC50
dosage of Brt for 48h.
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hTERT phosphorylation (which enables its activity) was determined
by immunoprecipitation. 500-1000 μg of protein were precipitated
with anti-phosphoserine antibody or with anti-total hTERT
antibody. Brt caused ~60% and 40% reduction in the levels of the
phosphorylation of hTERT protein in HBL-2 and NCEB,
respectively (Figure 4A). Telomerase is phosphorylated by the two
kinases: AKT and PKCα. The possible effects of Brt on the
phosphorylated form of AKT and PKCα were monitored by Western
blot analysis using specific p-AKT/p-PKCα and AKT/PKCα
antibodies. Brt caused 20% and 35% reduction in the level of the
phosphorylated form of AKT in HBL-2 and NCEB, respectively
(Figure 4B). The phosphorylation levels of PKCα decreased
approximately by 50% in both MCL cell lines (Figure 4C).
Mononuclear cells obtained from one patient were exposed to 2 ng/ml
bortezomib ex vivo, and the phosphorylation level of PKCα was
determined. Phospho-PKCα level decreased by 60% following Brt
treatment compared to the untreated patient cells (Figure 4D). To
understand whether this inhibition was due to a lower kinase activity or a
higher phosphatase activity we followed the expression of PP2A in our
system. Brt caused a slight increase in total protein phosphatase level of all
PP2A subunits in HBL-2 cells and not in NCEB cells (Figure 4H, I).The effect of rapamycin treatment on proliferation of MCL cell lines
The proliferation of HBL-2 and NCEB cells was evaluated after the
exposure of the cells to rapamycin for 48 h. The cells were grown in
the presence of the indicated rapamycin concentrations and cellproliferation was determined by the WST-1 assay. Rapamycin had a
cytostatic effect on MCL cells. HBL-2 cells reached a maximal
inhibitory effect of 40% at 30nM rapamycin after 48 h of exposure
(Figure 5A). NCEB cells reached a plateau curve at 2nM of
rapamycin (Figure 5A).
The combined effect of bortezomib and rapamycin on cell
proliferation and telomerase activity
MCL cell lines were exposed to several concentrations of
rapamycin with or without Brt for 48 h. The proliferative effect of
the combined treatments of Brt and rapamycin did not enhance the
cells proliferation, as the extent of proliferation inhibition of the
combined treatments was similar to that of each drug alone (Figure 5B).
However, when TA of cells treated both with Brt and rapamycin was
compared to its activity in cells treated with each drug alone, the effect
was totally different. Both HBL-2 and NCEB exhibited a synergistic
effect on TA (Figure 5 C, D). The synergistic effect was calculated
according to the following formula:
S ¼ X Bð Þ  X Rð Þ
100
 
≥X BþRð ÞS Synergism;
X(B) % of TA after bortezomib exposure;
X(R) % of TA after rapamycin exposure;
X(B+R) TA after bortezomib and rapamycin.
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Figure 3. The transcriptional regulation of telomerase activity in response to Brt exposure. The expression of hTERT after Brt treatment.
Cells were exposed to the IC50 of Brt for 16h or 24h and the expression of hTERT wasmeasured in the cells. A. HBL-2 cells; B. NCEB cells.
ChIP assay demonstrating the binding of SP1, C- Myc and NFkB to the hTERT promoter. C. An example of the ChIP assay, D. Chip assay
using HBL-2 cells; E. ChIP assay using NCEB cells.
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5 nM rapamycin should reduce TA by 20% but it actually reached
40% reduction. At 1 ng/ml Brt and 10 nM rapamycin, the expected
combined effect should reduce TA by 40% but it actually reached
70% reduction. Likewise, at 1.5 ng/ml Brt and 5 nM rapamycin, the
expected combined effect should reduce TA by 45% but it actually
reached 70% reduction. At 1.5 ng/ml Brt and 10 nM rapamycin, the
expected combined effect should reduce TA by 55% but it actually
reached 80% reduction. Similarly, in NCEB cells the synergism was
as follows: The expected reduction in TA when combining 2 ng/ml
Brt with 5 nM rapamycin was 50% but it was 80% in fact.
Combining 2 ng/ml Brt with 10 nM rapamycin resulted in 80%
reduction in TA instead of 55%; Combining 3 ng/ml Brt with 5 nM
rapamycin resulted in 65% reduction in TA instead of 25%; and3 ng/ml Brt with 10 nM rapamycin resulted in 82% reduction in TA
instead of 50%.
Discussion
Our results (summarized in Table 2) demonstrate the ability of Brt to
inhibit TA in MCL cells by decreasing the hTERTmRNA expression
and the phosphorylation of the catalytic subunit hTERT by its
kinases. HBL-2 and NCEB cells exhibited differential sensitivity to
the anti proliferative effect induced by Brt. HBL-2 cells were found to
exhibit a higher sensitivity to the drug than NCEB cells. In addition,
SK-N-MC cells (Ewing Sarcoma) representing cancer cells, and
keratinocytes (epithelial skin cells) also showed a high sensitivity to
Brt. when The effect of the drug on SK-N-MC after 48 h of exposure
was cytotoxic, while at 24 h it was probably cytostatic (Figure 4). The
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general and not related only to MCL cells. The effect of Brt on TA
differed between the two cell lines of MCL. Telomerase activity is
highly variable among cancer cells and is specific for each one. The
HBL-2 cells showed a substantial decrease in TA after 24 h of
exposure to Brt. This decrease in TA persisted after 48 and 72 hours
also. On the other hand, NCEB cells were more resistant to Brt and
the decrease in TA occurred 48 h post exposure. It is inhibited
wherever it is expressed, in all kinds of cells. The increase in TA
during 24-72 h exposure of HBL-2 cells to the drug may stem from
the fact that the drug was not stable in the growth media and
degraded during cell exposure. Of note, since Brt could inhibit
cellular proteasome activity much prior to that, even after 15 min, the
changes are probably caused by that inhibition as expected.
TA is regulated at multiple levels, including transcription, mRNA
splicing, maturation and modifications of hTR and hTERT,* pv=0.000; **pv
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Figure 4. (Continued).
748 Effect of Bortezomib on Telomerase Uziel et al. Translational Oncology Vol. 7, No. 6, 2014Post-translational changes of telomerase were evaluated by the
determination of the phosphorylated hTERT and of its kinases levels,
which phosphorylate telomerase to an active form. We show that Brt
inhibits the phosphorylation of the hTERT protein. Western blot
analysis revealed a slight decrease in phospho-AKT in the two MCL
cell lines. Other studies have shown different effects of Brt on p-AKT,
depending on the cell line. In the work of Kuen-Feng Chen et al., Brt
down-regulated p-AKT in a dose- and time-dependent manner in all
sensitive hepatocellular carcinoma cells, whereas no alterations of p-
AKT were found in PLC5 cells. In contrast, the effect of Brt on p-
PKCα was stronger and similar in these two cell lines. Accordingly,
the reduction of p-hTERT may be mediated mainly by a decrease in
the level of p-PKCα. Our data are consistent with other reports
showing that AKT and PKCα directly control phosphorylation and
activity of hTERT protein [3,7]. Another telomerase regulator is
PP2A, which deactivates telomerase by dephosphorylation (He [10]).
The treatment by Brt caused a slight increase in total protein
phosphatase level of all PP2A subunits in HBL-2 cells, whereas no
alterations of PP2A were found in NCEB cells. Together, these results
suggest that Brt reduces TA via transcriptional – reduction in hTERTmRNA level and post-translational modifications – a decrease in the
phosphorylated form of the enzyme.
The ex vivo exposures of mononuclear cells isolated from three MCL
patients to Bortezomib showed variable effects on TA activity. These
differences may reflect the resistance or sensitivity of MCL patients to
chemotherapy with Brt and may therefore be clinically relevant.
The m-TOR inhibitor rapamycin has been reported to be active
against MCL cells [13]. In the work by C. Zhou et al., 2003 it was
demonstrated that rapamycin potently reduces TA by decreasing the
hTERT mRNA level in endometrial cancer cells. Previous studies
showed that rapamycin synergies with Brt to enhance its cytotoxicity
in MCL lines, in vitro [9]. In this work, we show for the first time that
Brt and rapamycin synergistically reduce TA in MCL cell lines
(Figure 5). This is important in light of the fact that TA in NCEB
cells, which appeared to be relatively resistant to Brt was reduced by
the drug combination. Although there was no anti proliferative
advantage when the two drugs - Brt and rapamycin were used
together, the fact the two drugs induced a synergistic decrease in TA
activity may bear an anti- cancer advantage, at least for the long run
(e.g. shortening of telomers) in MCL. However, the inspected
Translational Oncology Vol. 7, No. 6, 2014 Effect of Bortezomib on Telomerase Uziel et al. 749sensitivity of the keratinocytes to Brt should be taken into
consideration if and when the results of our study will be translated
into clinical usage.
MCL is a Non-Hodgkin’s lymphoma characterized by an aggressive
course, a poor prognosis and a low chemosensitivity to common drugs
[12]. This work suggests that Brt may be a potentially useful component
of targeted therapy against MCL and that loss of TA in vitro and ex vivo
may be a good surrogate biomarker for predicting the anti-tumor activity
of the sensitivity. In addition, evidence of synergistic influence of
proteasome and m-TOR inhibitors on TA provides the framework for
clinical studies in which the combination of both agents will be
administered to patients with MCL.
In the light of the crucial role of telomerase in cancer cells, it was
important to characterize the possible relation between TA and BrtA
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Figure 5. The effects of Rapamycin on the proliferation and the a
Rapamycin for 48 h and their proliferation in response to thedrugwas exa
effect of the combined treatments of Bortezomib and Rapamycin on cell
of Brt and Rapamycin in HBL-2 and NCEB cells respectively. Drug conceand to distinguish the biochemical mechanism of its regulation. The
phenotype of a given cell after exposure to the proteasome inhibitor
results from the effects of many signal transduction processes that are
either inhibited or catalyzed by that treatment. Therefore, we cannot
exclude the possibility that additional routes may be involved in the
regulation of telomerase inhibition and therefore other intra-cellular
mechanism should be examined in these settings. We are also aware to
the fact that some of the changes reported here are only moderate.
Another potentially significant point is the possibility of getting an
anti-cancer synergistic effect in MCL cells from a drug combination
such as Brt and GRN163L (Imetelstat), a very effective telomerase
inhibitor which is clinically evaluated in numerous cancer types.
Hopefully the results of the clinical studies will be translated to
improved treatment for MCL patients.6 7 8 9
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Table 2A. A Summary of the Changes Induced by Bortezomib in MCL Cells
Cells Effect Change Extent
NCEB cells proliferation IC50 =5-2ng/ml
HBL-2 cells proliferation IC50 =2.5-1.5ng/ml
SK-N-MC cells proliferation IC50 =20ng/ml
keratinocytes proliferation IC50 =4-7.5ng/ml
NCEB cells TA No effect
HBL-2 cells TA ↓45-80%
mononuclear cells isolated
from MCL patients
TA ↓0-80%
SK-N-MC cells TA ↓20-70%
keratinocytes TA ↓25-70%
NCEB cells hTERT expression ↓30% and 5%
HBL-2 cells hTERT expression ↓45% and 25%
NCEB cells SP-1 Transcription factor binding to
the hTERT promoter
↓40%
HBL-2 cells SP-1 Transcription factor binding to
the hTERT promoter
↓50%
HBL-2 cells NFκB Transcription factor binding to
the hTERT promoter
↓65%
HBL-2 cells c-Myc Transcription factor binding to
the hTERT promoter
↓58%
NCEB cells Phosphorylation of telomerase ↓40%
HBL-2 cells Phosphorylation of telomerase ↓60%
NCEB cells Phosphorylation of AKT ↓20%
HBL-2 cells Phosphorylation of AKT ↓35%
NCEB cells Phosphorylation of PKCα ↓50%
HBL-2 cells Phosphorylation of PKCα ↓50%
mononuclear cells isolated
from MCL patients
Phosphorylation of PKCα ↓60%
NCEB cells Expression of PP2A No change
NCEB cells Expression of PP2A A slight increase
Table 2B. A summary of the changes induced by rapamycin in MCL cells
Cells Effect Change extent
NCEB cells proliferation IC40 =2nM
HBL-2 cells proliferation IC40 =30nM
NCEB cells proliferation No synergistic or additive effect of Brt and rapamycin
HBL-2 cells proliferation No synergistic or additive effect of Brt and rapamycin
NCEB cells TA Synergistic effect of Brt and rapamycin expressed as↓40-80%
HBL-2 cells TA Synergistic effect of Brt and rapamycin expressed as ↓20-80%
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